TIFFANY YOCUM: Open Payments
NPI 1114437738 · OWENSBORO, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,545 in 240 payments from 18 companies in 2025. Trend: 2023 $2,931 · 2024 $2,973 · 2025 $3,545
Food & beverage: $3,433Education: $111
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 30 | $514 |
| ABBVIE INC. | 37 | $450 |
| Otsuka America Pharmaceutical, Inc. | 23 | $289 |
| Teva Pharmaceuticals USA, Inc. | 11 | $283 |
| Alkermes, Inc. | 16 | $267 |
| Axsome Therapeutics, Inc. | 19 | $254 |
| Vanda Pharmaceuticals Inc. | 11 | $248 |
| E.R. Squibb & Sons, L.L.C. | 22 | $236 |
| Janssen Pharmaceuticals, Inc | 19 | $220 |
| Neurocrine BioSciences, Inc. | 12 | $219 |
Products named: CAPLYTA, VRAYLAR, REXULTI, ARISTADA, Auvelity, COBENFY, INGREZZA, HETLIOZ.
Industry payments across KY — which companies pay providers there.
